11 September 2015 1 5K Report

I would like to know the pathological significance of enhanced expression of cyclin D1 in hairy cell leukemia (HCL) cells, but not expressed in HCL-like leukemias/lymphomas (HCL-variant and splenic marginal zone lymphoma). Cyclin D1 overexpression is known to be essential in the pathogenesis of mantle cell lymphoma (MCL) and amplified in solid tumors such as malignant melanoma. Cyclin D1 overexpression in HCL cells is caused by Wnt/beta-catenin signaling pathway? Given that vemurafenib, one of the BRAF(V600E) inhibitors, is effective for the treatment for difficult-to-cure HCL and decreases the expression of both CD25 and cyclin D1, what kind of molecular machinery is underlying the regulation of cyclin D1 as well as CD25?

More Go J Yoshida's questions See All
Similar questions and discussions